Compare HSY & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSY | INSM |
|---|---|---|
| Founded | 1894 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | HSY | INSM |
|---|---|---|
| Price | $181.12 | $206.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 19 |
| Target Price | ★ $179.41 | $178.71 |
| AVG Volume (30 Days) | 1.7M | ★ 2.7M |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.69 | N/A |
| Revenue | ★ $11,489,095,000.00 | $447,022,000.00 |
| Revenue This Year | $4.29 | $43.10 |
| Revenue Next Year | $3.63 | $128.25 |
| P/E Ratio | $27.00 | ★ N/A |
| Revenue Growth | 4.71 | ★ 30.34 |
| 52 Week Low | $140.13 | $60.40 |
| 52 Week High | $208.03 | $212.75 |
| Indicator | HSY | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 65.14 |
| Support Level | $180.21 | $202.27 |
| Resistance Level | $189.49 | $212.75 |
| Average True Range (ATR) | 3.62 | 6.76 |
| MACD | 0.51 | -0.59 |
| Stochastic Oscillator | 29.46 | 74.74 |
Hershey is a leading US confectionery manufacturer (around a $54 billion market, according to Euromonitor), controlling around 36% of the domestic chocolate aisle. Beyond its namesake label, the firm's portfolio has expanded over the last 85 years and now comprises 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the US, including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confectionery business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its portfolio, as well as Pirate Brands and Dot's Pretzels over the past few years.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.